Protagen AG Gains CE Mark for Systemic Sclerosis Test

Protagen AG has secured CE marking for its Multilisa BICD2 test for the diagnosis of systemic sclerosis, the company announced Wednesday.

The test uses the company’s SeroTag technology platform to identify autoantibodies to BICD2, which are discovered in roughly 30 percent of patients with systemic sclerosis, according to the company. — Anisa Jibrell